...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: What's going on with the Phase 2 ZEN-3694 mCRPC trial?

Who is paying for keeping on the lights and paying for the trials this entire year,   Will we get any info from management ???

Share
New Message
Please login to post a reply